Don't Order That Peptide Yet: What Every Medspa Owner Needs to Understand About Last Week's FDA Peptide Ruling
- Rebecca Landriault
- 11 minutes ago
- 4 min read
If you've spent any time on social media over the last week, you've probably seen the headlines:
"The FDA approved peptides."
"Peptides are back."
"Now is the time to add BPC-157 to your practice."
Slow down.
As with many regulatory stories in aesthetics, the internet moved much faster than the facts.
Last week, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on recommendations regarding several commonly discussed peptides. While this has generated significant excitement throughout the wellness and aesthetics industries, many practice owners are misunderstanding what actually happened—and making business decisions based on incomplete information.
This is exactly the kind of moment where strong leadership matters.
What Actually Happened With The FDA Peptide Ruling for Medspas
The FDA's advisory committee reviewed several peptides that have been the subject of ongoing discussion within regenerative medicine and wellness, including compounds such as BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon.
The committee's vote is not the same as FDA approval.
Instead, the committee made recommendations to the FDA. The FDA will ultimately decide whether to accept, modify, or reject those recommendations as part of its regulatory process.
In other words: Nothing about your compliance obligations changed overnight.
The Biggest Mistake I See Practices Make
I've worked in aesthetics for over twenty years—as a practice owner, as a laser industry executive, and now as a consultant to practices across the country.
Whenever a new treatment category gains momentum, I see the same pattern.
Practices become afraid of being left behind. Instead of asking, "Should we offer this?" they immediately ask, "How quickly can we start?"
Those are two very different questions.
Being first rarely creates long-term success. Being prepared does!
Before You Add Any Peptide Program...
If you're considering adding peptides to your practice, your first purchase shouldn't be product.
It should be a plan.
That plan should include:
Confirmation that the therapy aligns with current federal and state regulatory requirements.
Review by your medical director or supervising provider.
Verification that your pharmacy and sourcing partners meet appropriate standards.
Updated informed consent documents.
Standing orders and clinical protocols.
Staff education and competency training.
Patient screening criteria and exclusion guidelines.
Marketing materials that accurately represent the treatment without making unsupported claims.
Documentation workflows that protect both patients and providers.
Notice what's missing from that list? Ordering inventory.
Compliance Is a Competitive Advantage
One of the biggest misconceptions in aesthetics is that compliance slows down growth.
In reality, compliance allows sustainable growth. Practices that implement new services thoughtfully build patient trust, reduce legal risk, and create operational consistency.
Practices that chase trends without infrastructure often spend the following year correcting documentation, training, billing, marketing, and regulatory issues that could have been avoided.
I've seen both.
The second path is always more expensive.
Ask Yourself These Questions
Before introducing any new peptide therapy, following the FDA ruling for medspas, ask yourself:
Can every team member accurately explain what this treatment is—and what it is not?
Are our consent forms current?
Have we reviewed applicable regulations in every state where we practice or provide telehealth services?
Does our marketing accurately reflect the available evidence?
Do we have written protocols for prescribing, dispensing, follow-up, and adverse event management?
If we were audited tomorrow, would we feel confident in our documentation?
If the answer to any of those questions is "no," your next investment shouldn't be in peptides. It should be in your systems.
The Bottom Line
The FDA's recent advisory vote is certainly worth paying attention to. But it isn't a green light to rush into offering new therapies. Successful practices don't win because they're first to every trend.
They win because they build the operational foundation that allows them to adopt new treatments safely, compliantly, and profitably.
The next decade in aesthetics won't belong to the practices offering the most services.
It will belong to the practices that implement those services the right way.
At Apex Aesthetic Consulting, we help aesthetic practices build the operational systems, compliance infrastructure, clinical documentation, and strategic planning needed to confidently introduce new treatments while protecting both patients and the business. Because growth without structure isn't growth—it's risk.
Disclaimer
The information provided in this article is intended for educational and informational purposes only and should not be construed as legal, medical, regulatory, or business advice. Regulatory requirements governing peptide therapies, compounded medications, telehealth, and aesthetic medical practices vary by state and are subject to change. Practice owners are responsible for ensuring compliance with all applicable federal, state, and local laws, as well as the policies of their medical director, collaborating providers, and pharmacy partners.
Before implementing any new treatment, service, or medication protocol, consult with qualified legal counsel, your medical director, and other appropriate healthcare or regulatory professionals to determine what is permissible within your specific practice and jurisdiction.
The opinions expressed in this article are those of Rebecca Landriault and Apex Aesthetic Consulting and are based on industry experience and operational best practices. This content does not establish a consultant-client relationship and should not be relied upon as a substitute for individualized legal, clinical, or regulatory guidance.
Comments